

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

RESIGNATION OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of AIM Vaccine Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that:

1. **Ms. Aijun WANG** (“**Ms. Wang**”) has tendered her resignation as a non-executive Director and a member of the compliance and risk control committee of the Company (the “**Compliance and Risk Control Committee**”) due to change in work arrangements, with effect from April 13, 2025; and
2. **Mr. Hui OUYANG** (“**Mr. Ouyang**”) has tendered his resignation as an independent non-executive Director, a member of the audit committee of the Company (the “**Audit Committee**”) and the strategy committee of the Company (the “**Strategy Committee**”), and the chairman of the nomination committee of the Company (the “**Nomination Committee**”) due to change in work arrangements, with effect from April 13, 2025.

Ms. Wang and Mr. Ouyang confirmed that (i) they have no disagreement with the Board; and (ii) there are no other matters relating to their respective resignations that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its sincere gratitude to Ms. Wang and Mr. Ouyang for their valuable contributions to the Company during their respective terms of service.

Pursuant to Rule 3.21 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Audit Committee must comprise a minimum of three members. Following the resignation of Mr. Ouyang as a member of the Audit Committee, the Audit Committee consists of two members only, namely Professor Ker Wei PEI and Mr. Xiaoguang GUO, each an independent non-executive Director, thus failing to meet the requirements of Rule 3.21 of the Listing Rules.

Pursuant to Rule 3.27A of the Listing Rules, the Nomination Committee must be chaired by the chairman of the Board or an independent non-executive Director and comprising a majority of independent non-executive Directors. Following the resignation of Mr. Ouyang as the chairman of the Nomination Committee, the Nomination Committee consist of Mr. Yan ZHOU, an executive Director, and Mr. Xiaoguang GUO, an independent non-executive Director, thus failing to meet the requirements of Rule 3.27A of the Listing Rules.

The Company will take measures to meet the requirements of Rule 3.21 of the Listing Rules as soon as practicable and in any event within three months from April 13, 2025 in accordance with Rule 3.23 of the Listing Rules and the requirement of Rule 3.27A of the Listing Rules as soon as practicable. Further announcement(s) will be made by the Company upon the appointment of the relevant member(s) in the Audit Committee and Nomination Committee.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
Chairman of the Board,
Executive Director and Chief Executive Officer

Hong Kong, April 13, 2025

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive Directors; Mr. Jichen ZHAO as non-executive Director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive Directors.